--- arxiv_id: PMC12912003 title: "Inhalation: A Smart Strategy and Increasing Potential for Drug Delivery." authors: - Wang SC - Kuo TH - Rai CI - Chen YC difficulty: Intermediate tags: - Inhalation - Drug Delivery - Pulmonary - Pharma published_at: 2026 flecto_url: https://flecto.zer0ai.dev/papers/PMC12912003/ lang: en --- ## Abstract Inhaled drug delivery is a critical and evolving strategy in modern medicine, offering distinct advantages over oral, intravenous, and transdermal routes. Inhalation provides rapid onset , high local drug concentrations , reduced systemic side effects , and improved patient compliance . Beyond its established role in treating respiratory diseases like asthma and COPD, recent advances have expanded its applications to systemic therapies, vaccines, and biologics. Innovative devices—including dry powder inhalers, soft mist inhalers, and smart inhalers integrated with digital health technologies—enable precise dosing, adherence monitoring, and personalized therapy. Emerging trends such as inhaled nanoparticles, gene and RNA therapies, and inhaled vaccines are redefining the landscape. Despite progress, challenges remain in formulation stability, device compatibility, inter-patient variability, and environmental concerns. Future research should prioritize green technologies, telehealth integration, patient-specific inhaler matching, and broader therapeutic applications beyond pulmonary diseases. ## Conclusion Inhalation drug delivery offers unique advantages including rapid onset, high local concentration, reduced systemic side effects, and non-invasive self-administration. Innovation is rapidly expanding applications beyond traditional respiratory diseases to systemic therapies, vaccines, and gene therapy. Smart inhalers and digital health technologies are enabling a new era of precision and personalized respiratory medicine. Remaining challenges—formulation stability, device compatibility, inter-patient variability, and environmental impact—require interdisciplinary research. As device engineering, digital health, and biopharmaceutical research converge, inhalation therapy is becoming an essential component of precision and patient-centric medicine. ## References Bamgbade OA, Richards RN, Mwaba M, et al. Factors affecting pain perception during administration of local anesthetics. 2015. ### Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261-1268. Darji MA, Lalge RM, Marathe SP, et al. Excipient stability in oral solid dosage forms. AAPS PharmSciTech. 2018;19(1):12-20. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors. Br J Clin Pharmacol. 2003;56(6):588-599. ### Newman SP. Drug delivery to the lungs: challenges and opportunities. Ther Deliv. 2017;8(8):647-661. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6(1):67-74. Borghardt JM, Kloft C, Sharma A. Inhaled therapy in respiratory disease. Handb Exp Pharmacol. 2018;254:1-25. Ibrahim M, Verma R, Garcia-Contreras L. Inhalation drug delivery devices. J Control Release. 2015;219:139-148. Lavorini F, Fontana GA, Usmani OS. New inhaler devices. Expert Opin Drug Deliv. 2014;11(10):1567-1583. ### See full reference list in the original paper (96 citations total). ## Hero, Button ### Read on PMC ↗ ## Abstract, Heading ### Abstract ## Routes, Heading ### Routes of Drug Administration ## Routes Drug delivery is a critical factor in disease therapy and prevention, directly influencing drug safety and effectiveness. Multiple delivery systems exist, each with distinct characteristics. The choice of route depends on three key factors: ## Routes, Card Heading ### Drug Nature ### Drug Action ### Patient Compliance ## Routes, Card Chemical properties (sensitivity to stomach acid or digestive enzymes), solubility (fat-soluble vs water-soluble), molecular size and structure, and stability against heat, light, or oxygen. Sites of action (systemic like blood pressure medication vs local like eye drops), required release rate (rapid onset vs sustained release), and accessibility of target cells or organs (some areas like the blood-brain barrier require special designs). Age and physical condition (infants or elderly may not tolerate injections or large pills), acceptability (some patients prefer oral or inhaled over injections), and convenience (complex dosage forms may reduce adherence). ## Routes, Table Heading ### Table 1: Comparison of Drug Delivery Systems ## Routes, Figcaption Figure 2: Cross-section diagram showing how different drug delivery methods penetrate skin layers. From left: topical cream, transdermal patch, intravenous injection, intramuscular injection, subcutaneous injection, and microneedle. The diagram illustrates the anatomical layers—stratum corneum (10–40 µm), epidermis (50–150 µm), and dermis (1500–4000 µm)—and each method's penetration depth. ## Why Inhalation, Heading ### Why Inhalation Drugs Are Important ## Why Inhalation, Card Heading ### Direct Delivery to the Lungs ### Effective for Respiratory Diseases ### Lower Dosage Requirements ### Reduced Systemic Side Effects ### Non-Invasive and Convenient ### Potential for Systemic Delivery ## Why Inhalation, Card Inhalation delivers drugs directly to the respiratory tract, achieving high local concentrations with rapid absorption through the vast alveolar surface area. First-line treatment for asthma and COPD. Bronchodilators and corticosteroids delivered directly where they are needed most. Targeted delivery means smaller doses can achieve therapeutic levels, reducing the total drug burden on the body. By targeting the lungs directly, inhalation minimizes whole-body drug exposure and its associated side effects. No needles required. Patients can self-administer with portable devices, improving compliance and quality of life. The lungs' large surface area and thin membrane enable absorption of biologics like insulin, vaccines, and gene therapies into the bloodstream. ## Why Inhalation, Figcaption Figure 1: Basic mechanism of inhalation drug delivery. The diagram shows an inhaler device (left) and the human upper airway (right), illustrating the two routes of inhalation: through the mouth (oral) and through the nostril (nasal), both reaching the trachea. ## Types, Heading ### Types of Inhalation ## Types Inhalation drug delivery can be divided into two main categories: nasal inhalation (targeting the nasal mucosa and olfactory region, with potential CNS access) and oral inhalation (targeting the lungs and alveoli for respiratory and systemic therapy). Each approach has distinct characteristics, applications, and limitations. ## Types, Table Heading ### Table 2: Nasal vs Oral Inhalation Comparison ## Devices, Heading ### Devices Used for Inhalation ## Devices, Table Heading ### Table 3: Inhalation Device Types ### Table 4: Green Inhaler Technology ## Emerging Trends, Heading ### Emerging Trends in Inhalation Drug Delivery ## Emerging Trends, Card Heading ### Smart Inhaler Technology ### Inhaled Biologics ### Nanoparticles & Liposomal Formulations ### RNA & Target Therapies ### Inhaled Vaccines ### Personalized Inhalation Therapy ## Emerging Trends, Card ### Digital inhalers with sensors for dose tracking and adherence monitoring ### Bluetooth-enabled devices that sync with apps for remote patient management ### AI integration for predictive maintenance of inhalation therapy in chronic diseases Biologic drugs delivered directly to the lungs via inhaler, enabling rapid absorption through the lung's large surface area ### Peptides, proteins, and antibodies are being reformulated for pulmonary delivery ### Nanocarriers improve drug stability, absorption, and enable sustained release ### Targeted delivery to specific lung tissues through engineered nanoparticles ### Pulmonary delivery of siRNA, mRNA, and CRISPR-Cas components directly to lung cells ### Targeting diseases like cystic fibrosis, lung cancer, pulmonary hypertension, and COVID-19 Needle-free, mucosal immunity-inducing formulations that intercept pathogens at the first line of defense ### Induction of triple immunity: humoral, cellular, and mucosal ### COVID-19 accelerated research into inhaled mRNA and adenovirus-based vaccines ### Drugs and inhalers specifically designed to suit individual patient needs ### Pharmacogenomics and AI algorithms help customize treatment regimens ### Patient-specific inhaler-device matching based on inspiratory flow profile ## Personalized, Heading ### Personalized Inhalation Therapy: A Cystic Fibrosis Case Study ## Personalized Personalized inhalation therapy represents the frontier of precision medicine applied to respiratory drug delivery. By tailoring drug selection, inhaler device, and dosing regimen to each patient's genotype and lung function, outcomes can be significantly improved. Cystic fibrosis (CF) serves as a compelling case study for this approach. ## Personalized, Callout Heading ### CF Treatment Pipeline ## Personalized, Callout Three inhaled antibiotics ( tobramycin , aztreonam , and colistimethate ) have been approved for use in patients with cystic fibrosis. Chronic airway infection is a hallmark of the disease, and individualized selection and rotation of inhaled antibiotics--including off-label use--can yield satisfactory therapeutic outcomes. Additionally, personalized phage therapy offers a promising strategy to address antimicrobial-resistant infections in CF patients. ## Personalized, Card Heading ### Successes ### Challenges ## Personalized, Card Targeted delivery of inhaled antibiotics achieves high local drug concentrations while limiting systemic exposure Individualized antibiotic selection and rotation yields satisfactory therapeutic outcomes in chronic airway infections Adherence to simplified once-daily inhalation dosing is significantly higher than multiple daily inhalations Intrinsically or acquired antibiotic-resistant organisms limit effectiveness of conventional inhaled antibiotics ### Heterogeneity in airway obstruction and mucus accumulation leads to uneven aerosol deposition Personalized phage therapy and novel formulations require larger clinical trials to establish long-term efficacy and safety ## Challenges, Heading ### Challenges and Limitations ## Challenges Despite the many advantages of inhalation drug delivery, significant challenges remain that must be addressed for the field to reach its full potential: ## Perspectives, Heading ### Perspectives and Future Directions ## Perspectives, Card Heading ### Green Technologies ### Telehealth Integration ### Patient-Specific Matching ### Beyond Pulmonary ## Perspectives, Card Developing environmentally friendly propellants and advancing propellant-free DPI technology to reduce the carbon footprint of inhaler use. Remote monitoring through smart inhaler data analytics, cloud-connected devices, and real-time adherence feedback for patients and clinicians. AI-driven inhaler selection based on individual inspiratory flow profiles, lung capacity, and disease characteristics. Expanding inhalation for systemic delivery of biologics, vaccines, and gene therapies—leveraging the lungs as a gateway to the bloodstream. ## Conclusion, Heading ### Conclusions ## References, Summary ### References (96 citations)